Results 1 to 10 of about 752,420 (346)

Longitudinal relationships between disability and gait characteristics in people with MS

Scientific Reports, 2022
Longitudinal data are vital in order to understand intra individual gait changes with the progression of multiple sclerosis (MS). Therefore, the primary aim of this study was to explore the relationship between changes in disability with changes in major
Sapir Dreyer-Alster, Shay Menascu, Mark Dolev, Uri Givon, David Magalashvili, Anat Achiron, Alon Kalron   +6 more
doaj   +1 more source

Targeted cognitive game training enhances cognitive performance in multiple sclerosis patients treated with interferon beta 1-a

Journal of NeuroEngineering and Rehabilitation, 2021
Background Prevention of cognitive decline in Multiple Sclerosis (MS) is of major importance. We explored the effect of a 6 months computerized game training program on cognitive performance in MS patients with mild cognitive impairment. Methods This was
Shay Menascu, Roy Aloni, Mark Dolev, David Magalashvili, Keren Gutman, Sapir Dreyer-Alster, Franck Tarpin-Bernard, Ran Achiron, Gil Harari, Anat Achiron   +9 more
doaj   +1 more source

The MULTI-ACT model: the path forward for participatory and anticipatory governance in health research and care

Health Research Policy and Systems, 2022
The COVID-19 pandemic has unmasked even more clearly the need for research and care to form a unique and interdependent ecosystem, a concept which has emerged in recent years.
Paola Zaratin, Deborah Bertorello, Roberta Guglielmino, Danilo Devigili, Giampaolo Brichetto, Valentina Tageo, Gabriele Dati, Stephanie Kramer, Mario Alberto Battaglia, Monica Di Luca   +9 more
doaj   +1 more source

The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control study. [PDF]

PLoS ONE, 2011
In the recently published meta-analysis of multiple sclerosis genome-wide association studies De Jager et al. identified three single nucleotide polymorphisms associated to MS: rs17824933 (CD6), rs1800693 (TNFRSF1A) and rs17445836 (61.5 kb from IRF8). To
International Multiple Sclerosis Genetics Consortium
doaj   +1 more source

Cognitive rehabilitation in multiple sclerosis: Three digital ingredients to address current and future priorities

Frontiers in Human Neuroscience, 2023
Multiple sclerosis (MS) is a neurological chronic disease with autoimmune demyelinating lesions and one of the most common disability causes in young adults.
Andrea Tacchino, Jessica Podda, Valeria Bergamaschi, Ludovico Pedullà, Giampaolo Brichetto, Giampaolo Brichetto   +5 more
doaj   +1 more source

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy

Neurology and Therapy, 2023
Background Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune responses in people with MS (PwMS) receiving different DMTs.
Aliya Jaber, Meera Patel, Andrew Sylvester, Mary Yarussi, J. Tamar Kalina, Jason P. Mendoza, Robin L. Avila, Matthew A. Tremblay   +7 more
doaj   +1 more source

RAM-589.555 favors neuroprotective and anti-inflammatory profile of CNS-resident glial cells in acute relapse EAE affected mice

Journal of Neuroinflammation, 2020
Background Targeting RNA polymerase-1 (POL1) machinery is a new strategy for suppression of multiple sclerosis (MS) relapse activity. Oral administration of POL1 inhibitor RAM-589.555, which is characterized by high permeability and bioavailability in ...
Rina Zilkha-Falb, Tatyana Rachutin-Zalogin, Lakota Cleaver, Michael Gurevich, Anat Achiron   +4 more
doaj   +1 more source

Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis

Vaccines, 2023
Vaccines against the SARS-CoV-2 virus were authorized for use by the Food and Drug Administration (FDA) in the United States and have proven effective for the prevention of morbidity and death from COVID-19.
Luke B. Elias, Aliya Jaber, Margarita Manzano, Mark Leekoff, Andrew Sylvester, Matthew A. Tremblay   +5 more
doaj   +1 more source

Cell-based therapeutic strategies for multiple sclerosis. [PDF]

, 2017
The availability of multiple disease-modifying medications with regulatory approval to treat multiple sclerosis illustrates the substantial progress made in therapy of the disease.
Cohen, Jeffrey A, International Conference on Cell-Based Therapies for Multiple Sclerosis, International Conference on Cell-Based Therapies for Multiple Sclerosis, International Conference on Cell-Based Therapies for Multiple Sclerosis, Pasquini, Marcelo, Reingold, Stephen C, Scolding, Neil J   +6 more
core   +1 more source

“I need personal experiences or some sort of documentation”: a qualitative study on where people with multiple sclerosis seek information on dietary and herbal supplements

BMC Complementary Medicine and Therapies, 2021
Background The use of dietary and herbal supplements (DIHES) is widespread among people with multiple sclerosis (PwMS). PwMS are a highly informed patient group, and they use several types of sources to seek information on subjects related to their ...
Sofie Bergien, Clara M. Petersen, Marie Lynning, Maria Kristiansen, Lasse Skovgaard   +4 more
doaj   +1 more source